Prognostic impact of elevated pre-treatment serum ferritin in patients with high risk MDS treated with Azacitidine

Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem cells that mainly affect the elderly, characterized by ineffective hematopoiesis, leading to cytopenia, infections, and a significant reduction in the quality of life [1,2]. Intensive chemotherapy combined with hematopoietic stem cell transplantation (HSCT) is the only curative treatment for this disease. However, it's applicability in elderly patients is limited by comorbidities and poor performance status. Azacytidine (AZA) significantly reduces transfusion dependence, decreases the risk of transformation to acute myeloid leukemia (AML), and improves the quality of life and overall survival (OS) in higher-risk MDS patients [3 –7].

Source: Experimental Hematology - June 5, 2018 Category: Hematology Authors: Kamel Laribi, Delphine Bolle, Mustapha Alani, Habib Ghnaya, Saga Le Bourdelles, Anne Besan çon, Jonathan Farhi, Nathalie Denizon, Alix Baugier de Materre Tags: Brief Communication Source Type: research